eligibility_summary
Eligible: Ph+ ALL adults untreated/minimally pretreated unfit for intensive chemo (MRD-only if in morphologic remission), or ≥12 yrs with relapsed/refractory Ph+ ALL or treated lymphoid blast-phase CML, ECOG≤2/Lansky≥50, weight≥40 kg, adequate liver, renal (CrCl≥30), pancreatic, cardiac, negative pregnancy test, contraception, consent. Exclude: uncontrolled infection, malignancy (<1‑yr survival), NYHA III–V HF, QTc>470 ms, major CNS disease (CNS leukemia ok), recent investigational/chemo (<7 d), pregnant/lactating.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Interventions: Blinatumomab (BiTE bispecific antibody construct, immunotherapy) engages CD3 on T cells and CD19 on B‑lymphoblasts to redirect T‑cell cytotoxicity. Asciminib (ABL001, small‑molecule STAMP allosteric tyrosine kinase inhibitor) binds the ABL myristoyl pocket to inhibit BCR::ABL1 signaling. Targets: CD19+ Philadelphia chromosome–positive B‑cell ALL blasts, T cells via CD3 engagement, and the BCR‑ABL1 oncogenic kinase pathway (including ABL1 kinase domain mutants). The combination aims to enhance immune‑mediated clearance while suppressing BCR‑ABL1–driven survival/proliferation.